Breast Cancer Start-up Challenge
Connect with Us
  • Winning Teams
  • Startups Launched
  • Phases
    • Start-up Phase
    • Eligibility & Rules
  • Resources
    • Inventions >
      • 1 Diagnostic from biopsies with software analysis
      • 2 Immunotherapy Using Modified Self Tumor Cells
      • 3 Combination of Tissue Reconstruction and Recurrence Prevention
      • 4 Human monoclonal Antibody Based Cancer Therapies
      • 5 Immunotherapy Using Granulysin Activated Monocytes
      • 6 Anti-cancer Toxin
      • 7 Versatile Delivery Method for Cancer Therapeutics
      • 8 Genomic Based Diagnostic Assay
      • 9 Tissue-based Diagnostic Assay
      • 10 Diagnostic Kit for Therapy Benefit Prediction
    • Seed Funders
  • Media
    • News and Past Events
  • Team Blogs
  • Teams
    • Teams Accepted
    • Core Team
    • Judges
    • Challenge Supporters
  • Contact Us

Welcome to Mesopharm Therapeutics

7/29/2014

0 Comments

 
Mesopharm Therapeutics officially launches on April 7th, 2014 after winning the Start-up phase of the Breast Cancer Startup Challenge (BCSC) (http://breastcancerstartupchallenge.com). Our talented team brings together people with diverse expertise and backgrounds from Stanford University (USA), University of Auckland (New Zealand), and University Medical Center Utrecht (Netherlands), reflecting the power of multidisciplinary and global collaboration. 


OUR MISSION:

At Mespharm, our goal is to revolutionize cancer therapies by combining state of the art therapeutics and theranostics. We envision to develop first-in-class biological therapies at a pre-clinical stage and to accelerate their transition into the clinic. Our flagship drug candidates target specific cell surface protein that is highly expressed in breast cancer and other tumors. We plan to extend our therapies beyond breast cancer to other devastating cancers where our drug candidates show indication for therapeutic use.

Milestones: 
  • Mesopharm won the BCSC on March 5th, 2014 and officially incorporated on April 7th, 2014.
  • Licensing application for two fields of use (FOU) submitted on April 15th, 2014; one FOU is on Federal Register notice on July 19th, 2014. 
  • Initiated conversation with potential industrial partnership with Pfizer, MedImmune/Astrazeneca, Celgene, Igenica,
  • Riverside Antibody. 
  • Have successfully secured full support of chemistry expertise on therapeutic drug development from the Auckland Cancer Society Research Centre, Thoracic Oncology Austin Hospital/Ludwing Cancer Centre, The Ferrier Institute (Wellington, NZ). 
  • Pitched to various venture capital firms: Harbert Venture Partners, Hatteras Venture Partners, Avalon Ventures, and Sanofi-Sunrise.
  • Expanded the Advisory Board in all disciplines; met with Roche Venture Fund, Mission Bay Capital, and Orbimed. 
  • Enrolled in QB3 for upcoming SBIR application.
0 Comments



Leave a Reply.

    Author

    Write something about yourself. No need to be fancy, just an overview.

    Archives

    November 2014
    August 2014
    July 2014
    April 2014
    February 2014
    January 2014

    Categories

    All
    Breast Cancer
    Breast Cancer Startup Challenge
    Duke
    Invention 3
    Invention 4
    Startup
    Tulane

    RSS Feed

The Center for Advancing Innovation, INC 2013